Trials / Completed
CompletedNCT04470778
Study to Assess the Effect of Acid-reducing Agent Famotidine on the Drug Levels of BMS-986256 in Healthy Participants
A Phase 1, Open-label, Crossover Study to Assess the Effect of Acid-reducing Agent Famotidine on the Pharmacokinetics of BMS-986256 in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 35 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to investigate the effect of gastric pH changes due to famotidine administration on the drug levels of prototype BMS-986256 tablet formulation in healthy participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986256 | Specified dose on specified days |
| DRUG | Famotidine | Specified dose on specified days |
Timeline
- Start date
- 2020-07-20
- Primary completion
- 2021-03-21
- Completion
- 2021-03-28
- First posted
- 2020-07-14
- Last updated
- 2025-02-06
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04470778. Inclusion in this directory is not an endorsement.